Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Agathe Vrillon

Showing results (31-40 of 55) with videos related to

Pageof 6
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 30, 2020
Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosisThomas K Karikari, Andreja Emeršič, Agathe Vrillon, et al.
Alzheimer'S Research & Therapy|October 19, 2024
Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting studyKarl Götze, Agathe Vrillon, Julien Dumurgier, et al.
Alzheimer'S Research & Therapy|December 21, 2024
Association of critically short telomeres with brain and blood markers of ageing and Alzheimer's disease in older adultsAsrar Lehodey, Perla Kaliman, Cassandre Palix, et al.
Alzheimer'S Research & Therapy|April 11, 2021
COVID-19 in adults with dementia: clinical features and risk factors of mortality-a clinical cohort study on 125 patientsAgathe Vrillon, Elsa Mhanna, Clément Aveneau, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 26, 2024
Cerebrospinal fluid p-tau181, 217, and 231 in definite Creutzfeldt-Jakob disease with and without concomitant pathologiesAndreja Emeršič, Nicholas J Ashton, Agathe Vrillon, et al.
Addiction Biology|October 27, 2022
Plasma tau, NfL, GFAP and UCHL1 as candidate biomarkers of alcohol withdrawal-associated brain damage: A pilot studyVirgile Clergue-Duval, Agathe Vrillon, Jérôme Jeanblanc, et al.
Acta Neuropathologica|July 27, 2022
Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer's diseaseAntonio Boza-Serrano, Agathe Vrillon, Karolina Minta, et al.
Alzheimer'S Research & Therapy|March 10, 2023
Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohortsJuan Lantero-Rodriguez, Agathe Vrillon, Aida Fernández-Lebrero, et al.
Acta Neuropathologica|January 6, 2024
CSF p-tau205: a biomarker of tau pathology in Alzheimer's diseaseJuan Lantero-Rodriguez, Laia Montoliu-Gaya, Andrea L Benedet, et al.
Neuroimage. Clinical|June 8, 2024
Translocator protein (TSPO) genotype does not change cerebrospinal fluid levels of glial activation, axonal and synaptic damage markers in early Alzheimer's diseaseDominique Gouilly, Agathe Vrillon, Elsa Bertrand, et al.
Pageof 6

Showing results (31-40 of 55) with videos related to

Sort By:
Pageof 6
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|November 30, 2020
Head-to-head comparison of clinical performance of CSF phospho-tau T181 and T217 biomarkers for Alzheimer's disease diagnosisThomas K Karikari, Andreja Emeršič, Agathe Vrillon, et al.
Alzheimer'S Research & Therapy|October 19, 2024
Plasma neurofilament light chain as prognostic marker of cognitive decline in neurodegenerative diseases, a clinical setting studyKarl Götze, Agathe Vrillon, Julien Dumurgier, et al.
Alzheimer'S Research & Therapy|December 21, 2024
Association of critically short telomeres with brain and blood markers of ageing and Alzheimer's disease in older adultsAsrar Lehodey, Perla Kaliman, Cassandre Palix, et al.
Alzheimer'S Research & Therapy|April 11, 2021
COVID-19 in adults with dementia: clinical features and risk factors of mortality-a clinical cohort study on 125 patientsAgathe Vrillon, Elsa Mhanna, Clément Aveneau, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|June 26, 2024
Cerebrospinal fluid p-tau181, 217, and 231 in definite Creutzfeldt-Jakob disease with and without concomitant pathologiesAndreja Emeršič, Nicholas J Ashton, Agathe Vrillon, et al.
Addiction Biology|October 27, 2022
Plasma tau, NfL, GFAP and UCHL1 as candidate biomarkers of alcohol withdrawal-associated brain damage: A pilot studyVirgile Clergue-Duval, Agathe Vrillon, Jérôme Jeanblanc, et al.
Acta Neuropathologica|July 27, 2022
Galectin-3 is elevated in CSF and is associated with Aβ deposits and tau aggregates in brain tissue in Alzheimer's diseaseAntonio Boza-Serrano, Agathe Vrillon, Karolina Minta, et al.
Alzheimer'S Research & Therapy|March 10, 2023
Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohortsJuan Lantero-Rodriguez, Agathe Vrillon, Aida Fernández-Lebrero, et al.
Acta Neuropathologica|January 6, 2024
CSF p-tau205: a biomarker of tau pathology in Alzheimer's diseaseJuan Lantero-Rodriguez, Laia Montoliu-Gaya, Andrea L Benedet, et al.
Neuroimage. Clinical|June 8, 2024
Translocator protein (TSPO) genotype does not change cerebrospinal fluid levels of glial activation, axonal and synaptic damage markers in early Alzheimer's diseaseDominique Gouilly, Agathe Vrillon, Elsa Bertrand, et al.
Pageof 6